Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 17/20 | 1.00 |
| ▸ | ACHE | P22303 | 17/20 | 1.00 |
| ▸ | PREP | P48147 | 17/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24212430 | 0.92 | BCHE (0.85) | BCHEACHEPREP | |
| SCHEMBL2742465 | 0.89 | BCHE (0.83) | BCHEACHEPREP | |
| Berberine SCHEMBL15669190 | 0.88 | ACHE (1.00) | BCHEACHEPREP | |
| Berberine SCHEMBL30153843 | 0.88 | ACHE (1.00) | BCHEACHEPREP | |
| Berberine SCHEMBL25632 | 0.88 | ACHE (1.00) | BCHEACHEPREP | |
| Berberine SCHEMBL29354144 | 0.88 | ACHE (1.00) | BCHEACHEPREP | |
| SCHEMBL26621113 | 0.87 | BCHE (0.80) | BCHEACHEPREP | |
| Berberine SCHEMBL1376273 | 0.86 | ACHE (0.98) | BCHEACHEPREP | |
| Berberine SCHEMBL4894622 | 0.86 | BCHE (0.98) | BCHEACHEPREP | |
| Berberine SCHEMBL21462194 | 0.86 | ACHE (0.98) | BCHEACHEPREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387403-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | CVI PHARMACEUTICALS LIMITED (KY) | 2022-12-08 | — | — | US | disclosed |
| EP-2370434-B1 | ISOQUINOLINYL-CONTAINING ALKALOID COMPOUNDS AND COMPOSITIONS USEFUL FOR REDUCING LIPID LEVELS | CVI PHARMACEUTICALS LTD (KY) | 2014-09-17 | — | — | EP | disclosed |
| US-8815900-B2 | Compounds and compositions for reducing lipid levels | CVI PHARMACEUTICALS LIMITED (KY) | 2014-08-26 | — | — | US | disclosed |
| US-20110269754-A1 | COMPOUNDS AND COMPOSITIONS FOR REDUCING LIPID LEVELS | CVI PHARMACEUTICALS LIMITED (KY) | 2011-11-03 | — | — | US | disclosed |
| US-8003795-B2 | Compounds and compositions for reducing lipid levels | CVI PHARMACEUTICALS LIMITED (KY) | 2011-08-23 | — | — | US | disclosed |
| US-20110009628-A1 | Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same | CVI PHARMACEUTICALS LIMITED (KY) | 2011-01-13 | — | — | US | disclosed |
| US-20090048246-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS | CVI PHARMACEUTICALS LIMITED (KY) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009628-A1 | Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same | LIPC, LDLR, PCSK9 | BCHE 693/4885ACHE 2778/4885PREP 3567/4885 |
| US-20220387403-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | LIPC, FABP1, CPT1A | BCHE 795/4885ACHE 2228/4885PREP 2464/4885 |
| US-20110269754-A1 | COMPOUNDS AND COMPOSITIONS FOR REDUCING LIPID LEVELS | LIPC, LIPE, BCHE | BCHE 3/4885ACHE 302/4885PREP 3065/4885 |
| US-20090048246-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS | LIPC, BCHE, LIPE | BCHE 2/4885ACHE 276/4885PREP 2963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.